The funding will enable the company in conducting Phase II human clinical trials for its potential drug candidate for ...

China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for ...

Patients with vitiligo may significantly improve the effectiveness of a commonly used light therapy — by nearly twofold— by ...

Ahammune Biosciences, a clinical-stage therapeutics company focused on developing new treatments for skin diseases, has ...

In addition to vitiligo, Mini also works with cancer survivors, helping to reconstruct areolas post-mastectomy, and individuals with burn scars or surgical marks. Her approach is deeply personal, ...

Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the EADV 2024 Congress ...

Biotech startup Ahammune Biosciences has raised $5 Mn (about INR 41 Cr) in its Series A round led by pi Ventures.

Vitiligo is a skin condition that’s little understood and it often takes a long time to diagnose, but now a new treatment could help to cure it. It currently affects around 70 million people around ...

Sunscreen plays a big role in managing vitiligo because it prevents sunburn and reduces the risk of skin cancer by protecting ...

VASI is a valid and reliable tool that is responsive to change and has defined thresholds for meaningful improvement for patients with vitiligo.

Drug maker AbbVie (ABBV) announced Wednesday positive results from a new post-hoc analysis of Phase 3 Studies, demonstrating efficacy ...